Sarcomas | Specialty

The OncLive Sarcomas/TGCT condition center page is a comprehensive resource for clinical news and expert insights on tenosynovial giant cell tumor (TGCT), soft tissue sarcoma, gastrointestinal stromal tumor, Ewing sarcoma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in sarcomas and TGCT.

Dr. Tap on Olaratumab in Patients With Soft Tissue Sarcoma

March 18th 2016

William D. Tap, MD, chief, Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the mechanism of action of olaratumumab as a treatment for patients with soft tissue sarcoma.

Demetri's Team Approach Translates Into Success in Sarcoma Research

February 10th 2016

George D. Demetri, MD, whose teamwork approach has helped pave the way for new drugs for hard-to-treat sarcomas, was honored in the Gastrointestinal Cancer category with a 2014 Giants of Cancer Care® award, a program that the Intellisphere® Oncology Specialty Group launched to honor leaders in the field.

FDA Grants T-Cell Therapy Breakthrough Designation in Sarcoma

February 9th 2016

An affinity enhanced T-cell therapy has received an FDA breakthrough therapy designation for the treatment of patients with inoperable or metastatic pretreated synovial sarcoma who harbor HLA-A*201, HLA-A*205, or HLA-A*206 alleles and whose tumors express the NY-ESO-1 tumor antigen.

FDA Approves Eribulin for Advanced Liposarcoma

January 28th 2016

The FDA has approved eribulin mesylate as a treatment for patients with advanced or unresectable liposarcoma following prior treatment with an anthracycline-based chemotherapy.

Immunotherapy Shows Early Promise in Advanced Sarcomas

December 7th 2015

Phase Ib/II research has shown promise for adoptive cellular therapy combined with ipilimumab in patients with advanced sarcomas.

Adding Olaratumab to Chemo Improves Survival in Soft Tissue Sarcoma

December 4th 2015

Combining olaratumab with doxorubicin reduced the risk of death by 54% versus doxorubicin alone in patients with advanced soft tissue sarcoma.

Adding Novel Antibody to Pazopanib Shows Promise in Soft Tissue Sarcoma

December 4th 2015

Combining the investigational antibody TRC105 with Votrient showed promising antitumor activity in patients with soft tissue sarcoma.

Dr. Trent on Sequencing Trabectedin for Patients With Soft Tissue Sarcoma

December 2nd 2015

Jonathan C. Trent, MD, associate director for Clinical Research, director of the Sarcoma Medical Research Program at the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, discusses sequencing trabectedin (Yondelis) for patients with soft tissue sarcoma.

Emerging Agents Poised to Advance Soft Tissue Sarcoma Care

November 17th 2015

With scores of subtypes and a paucity of molecular markers, soft tissue sarcoma remains a complex and challenging tumor type to treat yet significant strides being made in the field are likely to alter the therapeutic paradigm.

Dr. Philip on Olaratumab for Soft Tissue Sarcoma

November 6th 2015

Tony Philip, MD, medical oncologist, Monter Cancer Center of the North Shore-LIJ Cancer Institute, assistant professor of Medicine, Hofstra-North Shore LIJ School of Medicine and NYIT College of Osteopathic Medicine, discusses approved and emerging agents for soft tissue sarcomas.

Dr. Federman on Ongoing Research in Rare Bone and Soft Tissue Sarcoma

October 28th 2015

Noah Federman, MD, director, Pediatric Bone and Soft Tissue Sarcoma Program, University of California, Los Angeles (UCLA), discusses ongoing research in rare bone and soft tissue sarcoma.

FDA Approves Trabectedin in Soft Tissue Sarcomas

October 23rd 2015

The FDA has approved trabectedin for the treatment of patients with advanced soft tissue sarcoma, including liposarcoma and leiomyosarcoma subtypes, who have previously received chemotherapy that included an anthracycline.

Future Directions in Soft Tissue Sarcoma

October 21st 2015

Phase III Data on Eribulin in Advanced STS

October 21st 2015

Early Data With Olaratumab in Soft Tissue Sarcoma

October 21st 2015

Patient Selection in Soft Tissue Sarcoma

October 21st 2015

Use of Trabectedin in Soft Tissue Sarcoma

October 21st 2015

Subtyping in Soft Tissue Sarcoma: The PALLETTE Study

October 21st 2015

Chemotherapy Toxicity Considerations in Soft Tissue Sarcoma

October 21st 2015

Chemotherapy Regimens for Advanced Soft Tissue Sarcoma

October 21st 2015

x